Picture of Ergomed logo

ERGO Ergomed Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Momentum

Relative Strength (%)
1m+3.58%
3m+25.17%
6m+31.85%
1yr+6.69%
Volume Change (%)
10d/3m+71.06%
Price vs... (%)
52w High-2.46%
50d MA+0.19%
200d MA+19.04%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)26.5
PEG Ratio (f)1.92
EPS Growth (f)16.01%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value7.71
Price to Tang. Book19.98
Price to Free Cashflow41.7
Price to Sales4.61
EV to EBITDA27.13

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital20.26%
Return on Equity18.08%
Operating Margin12.81%

Financial Summary

Year End 31st DecUnit201820192020202120222023E2024ECAGR / Avg
Total Revenue£m54.1168.2586.39118.58145.26163.87182.1124.99%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/a+39.52+66.36-5.83+42.16+13.09n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Ergomed EPS forecast chart

Profile Summary

Ergomed PLC is a United Kingdom-based company that is primarily focused on providing specialized services to the biopharmaceutical industry. The Company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The Company serves over 100 countries. It operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company's subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
September 29th, 2000
Public Since
July 15th, 2014
No. of Employees
1,437
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
52,084,254

ERGO Share Price Performance

Upcoming Events for ERGO

Full Year 2023 Ergomed PLC Earnings Release

Similar to ERGO

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

FAQ